- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 231/12
Total number of patents in this class: 1950
10-year publication summary
|
165
|
185
|
159
|
166
|
150
|
164
|
121
|
146
|
113
|
25
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
53 |
| Bayer Cropscience AG | 2241 |
44 |
| Takeda Pharmaceutical Company Limited | 2961 |
41 |
| Arena Pharmaceuticals, Inc. | 381 |
34 |
| Epizyme, Inc. | 383 |
32 |
| Novartis AG | 11238 |
24 |
| Boehringer Ingelheim International GmbH | 4629 |
22 |
| BASF SE | 19740 |
20 |
| University of Southern California | 2016 |
20 |
| F. Hoffmann-La Roche AG | 7958 |
18 |
| AstraZeneca AB | 3042 |
17 |
| Janssen Pharmaceutica N.V. | 3839 |
17 |
| Merck Patent GmbH | 5909 |
16 |
| Bayer Animal Health GmbH | 300 |
16 |
| Corteva Agriscience LLC | 2494 |
16 |
| E. I. du Pont de Nemours and Company | 4345 |
15 |
| Sumitomo Chemical Company, Limited | 8808 |
15 |
| Merck Sharp & Dohme LLC | 3689 |
15 |
| Syngenta Participations AG | 4970 |
14 |
| Bayer Pharma AG | 1096 |
14 |
| Other owners | 1487 |